Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 8, 2017, Pages 748-750

  Kazi, Dhruv S ^a   Penko, Joanne ^a   Coxson, Pamela G ^a   Moran, Andrew E ^b   Ollendorf, Daniel A ^c   Tice, Jeffrey A ^d   Bibbins Domingo, Kirsten ^d  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART INFARCTION; HUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; UNITED STATES; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; HYPERCHOLESTEROLEMIA; QUALITY ADJUSTED LIFE YEAR;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9; QUALITY-ADJUSTED LIFE YEARS;

EID: 85028363311     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.9924     Document Type: Article

References (6)

1. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743-753.
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18): 1713-1722.
3. National Center for Health Statistics. National Health and Nutrition Examination Survey, 2005-2012. https://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed March 28, 2017.
4. Truven Health Analytics. Red Book Online. http://truvenhealth.com/products/micromedex/product-suites/clinical-knowledge/red-book/about. Accessed April 10, 2017.
5. Beasley D, Hummer C. Update 1—Amgen discounts cholesterol drug, but payers want more. http://www.reuters.com/article/heart-amgen-pricing-idUSL2N1GU23H. Accessed April 8, 2017.
6. Amgen. Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for Repatha (Evolocumab). https://www.amgen.com/media/news-releases/2017/05/amgen-and-harvard-pilgrim-agree -to-first-cardiovascular-outcomesbased-refund-contract-for-repatha -evolocumab/ Accessed June 10, 2017.